A Multi-centre, Comparative, Double Blind, Randomised Cross-over Trial Investigating Single Dose Pharmacokinetics and Safety of Turoctocog Alfa Pegol From the Pivotal Process and Turoctocog Alfa Pegol From the Commercial Process in Patients With Severe Haemophilia A

Phase 1

Completed

• Conditions: Congenital Bleeding Disorder; Haemophilia A
• Interventions: Drug: turoctocog alfa pegol

• Registration Number: NCT02920398
• Lead Sponsor: Novo Nordisk A/S

Brief Summary

Investigating single dose pharmacokinetics and safety of turoctocog alfa pegol from the pivotal process and turoctocog alfa pegol from the commercial process in patients with severe haemophilia A

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study First Submitted: 2016-09-29
• Study First Submitted QC: 2016-09-29
• Study First Posted: 2016-09-30
• Study Start: 2016-10-04
• Primary Completion: 2017-04-07
• Study Completion: 2017-04-07
• Status Verified: 2017-12
• Last Update Submitted: 2017-12-14
• Last Update Posted: 2017-12-15

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 21

Inclusion Criteria

• Informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial
• Ongoing participation in pathfinder™2
• Male, age at least 12 years at the time of signing informed consent (in certain countries the lower age limit will be 18 years, according to local requirements)

Read More

Exclusion Criteria

• FVIII inhibitors (≥0.6 BU) at last visit in pathfinder™2 prior to entry in pathfinder™7
• Planned surgery during the trial
• Major surgery performed within 4 weeks prior to screening
• Previous participation in this trial. Participation is defined as signed informed consent
• Any disorder, except for conditions associated with haemophilia A, which in the investigator's opinion might jeopardise patient's safety or compliance with the protocol

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
N8-GP pivotal	turoctocog alfa pegol	-
N8-GP commercial	turoctocog alfa pegol	-

Primary Outcome Measures

Name	Time	Method
Area under the FVIII activity-time curve	From 0 to 96 hours post injection

Secondary Outcome Measures

Name	Time	Method
Clearance in blood plasma of FVIII activity	From time of trial product administration to 96 hours post-dose
Terminal half-life	From time of trial product administration to 96 hours post-dose
Area under the FVIII activity-time curve from 0 to infinity	From time of trial product administration to 96 hours post-dose
Incremental recovery in blood plasma of FVIII activity	From time of trial product administration to 96 hours post-dose
FVIII activity 30 min post administration - dose normalised to 50 U/kg	From time of trial product administration to 96 hours post-dose

Trial Locations

Locations (1)

Novo Nordisk Investigational Site; 🇪🇸 Málaga, Spain